Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Kidney Cancer

Join Steven Chang, MD and Toni Choueiri, MD as they present their multidisciplinary expertise on a range of cases pertaining to kidney cancer.

To date, seven such agents have been approved by the FDA for the first- and second-line treatment of advanced RCC: sunitinib malate, sorafenib tosylate, temsirolimus, everolimus, bevacizumab in combination with interferon, pazopanib, and axitinib. This has led to a paradigm shift of treatment of kidney cancer from cytokine immunotherapy to targeted therapy and has significantly improved patient survival rates.

Prior to therapy selection, the patients are stratified in risks groups.  The most widely used prognostic factor model is from the Memorial Sloan-Kettering Cancer Center (MSKCC). However, the MSKCC prognostic risk profiles are derived from the era of immunotherapy and limited to a population of patients eligible for participation in immunotherapy clinical trials. A new prognostic model for patients with advanced RCC treated with VEGF-targeted therapy has recently been developed and validated known as the International Metastatic RCC Database Consortium or Heng’s model.

All patients with advanced RCC require best supportive care and advances have been in this area as well. Strategies have been developed to enhance tolerability of the targeted agents including dose reductions, schedule changes or alternative therapies. Progression/relapse and the need for subsequent lines therapy in patients with RCC are nearly universal. Sequencing the appropriate therapy for maximum benefit is critical.

Target Audience

This educational activity is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Apply NCCN Guideline-based therapeutic strategies for the treatment of patients with kidney cancer
  • Describe the multidisciplinary aspects of the management of patients with kidney cancer
  • Identify the key characteristics of  kidney cancer that trigger decision points
  • Recognize situations where optimal care may require adapting the Guideline recommendations to individual circumstances
Additional information
Supporters: 

Supported by educational grants from:

  • AstraZeneca
  • Exelixis Inc.
  • Genentech BioOncology
  • Janssen Biotech, Inc.
  • Novartis Oncology
  • Takeda Oncology

Supported by a grant from Onyx Pharmaceuticals.

Supported by independent educational grants from Merck and Prometheus Laboratories Inc.

Supported by an unrestricted, educational grant from Celgene Corporation.

Course summary
Available credit: 
  • 0.75 Participation
  • 0.70 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician
Course opens: 
04/03/2015
Course expires: 
04/03/2016
Cost:
$0.00

Steven Chang, MD
Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center

Toni Choueiri, MD
Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center

Available Credit

  • 0.75 Participation
  • 0.70 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician

Accreditation Period

Course opens: 
04/03/2015
Course expires: 
04/03/2016

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • For Windows: JavaScript and cookies enabled, Active X enabled and unblocked for Microsoft Internet Explorer, Java 6.0 or above
  • For Mac: JavaScript and cookies enabled, Plug-ins enabled in Safari, Java 6.0 or above
  • Adobe Reader or other PDF reader software for certificate viewing/printing